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Abstract
Background: Project Accept is a community randomized, controlled trial to evaluate the efficacy of community
mobilization, mobile testing, same-day results, and post-test support for the prevention of HIV infection in Thailand,
Tanzania, Zimbabwe, and South Africa. We evaluated the accuracy of in-country HIV rapid testing and determined
HIV prevalence in the Project Accept pilot study.
Methods: Two HIV rapid tests were performed in parallel in local laboratories. If the first two rapid tests were
discordant (one reactive, one non-reactive), a third HIV rapid test or enzyme immunoassay was performed. Samples
were designated HIV NEG if the first two tests were non-reactive, HIV DISC if the first two tests were discordant,
and HIV POS if the first two tests were reactive. Samples were re-analyzed in the United States using a panel of
laboratory tests.
Results: HIV infection status was correctly determined based on-in country testing for 2,236 (99.5%) of 2,247
participants [7 (0.37%) of 1,907 HIV NEG samples were HIV-positive; 2 (0.63%) of 317 HIV POS samples were
HIV-negative; 2 (8.3%) of 24 HIV DISC samples were incorrectly identified as HIV-positive based on the in-country
tie-breaker test]. HIV prevalence was: Thailand: 0.6%, Tanzania: 5.0%, Zimbabwe 14.7%, Soweto South Africa: 19.4%,
Vulindlela, South Africa: 24.4%, (overall prevalence: 14.4%).
Conclusions: In-country testing based on two HIV rapid tests correctly identified the HIV infection status for 99.5%
of study participants; most participants with discordant HIV rapid tests were not infected. HIV prevalence varied
considerably across the study sites (range: 0.6% to 24.4%).
Trial Registration: ClinicalTrials.gov registry number NCT00203749.
Background
Project Accept (HIV Prevention Trials Network [HPTN]
043) is a Phase III, community randomized, controlled
trial of community mobilization, mobile testing, same-day
results, and post-test support for the prevention of HIV
infection [1]. The primary objective of Project Accept is to
test the hypothesis that communities receiving three years
of community-based voluntary counseling and testing
(CBVCT) will have significantly lower HIV incidence com-
pared to communities receiving three years of standard
clinic-based VCT (SVCT) alone. In Project Accept, 34
communities in Africa (Soweto and Vulindlela, South
Africa) [2-4], Tanzania (Kisarawe), and Zimbabwe
(Mutoko) [5,6] and 14 communities in Thailand (Chiang
Mai) [7-9] were randomized to receive either a CBVCT
intervention in addition to SVCT services, or SVCT
services alone. The CBVCT intervention has four major
components: (1) to make VCT more available in commu-
nity settings, (2) to engage the community through out-
reach, (3) to provide post-test support, and (4) to provide
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These strategies were designed to change community
norms and reduce risk for HIV infection among all com-
munity members, irrespective of whether they participated
directly in the intervention.
The intervention began in January, 2006 and was com-
pleted in March, 2011. Samples are now being collected
from approximately 50,000 participants for the post-inter-
vention assessment. In preparation for analysis of the
post-intervention samples, a pilot study was performed
that involved collection and analysis of post-intervention
samples from approximately 2,500 individuals in addi-
tional, non-randomized SVCT communities across the
five study sites. In this report, we evaluated the accuracy
of in-country HIV testing and determined HIV prevalence
in the Project Accept pilot study.
Methods
Study participants
Participants were selected from all community residents
by cluster sampling based on households. Participating
households were selected randomly from the list of all
households in the community. Informed consent was
obtained from the head of a selected household and a list
of eligible household members. Eligibility criteria were age
between 18 and 32 years and residency in the community.
All eligible household members were invited to participate
in the pilot study. Written informed consent was obtained
from all study participants.
Sample collection
Blood samples were collected by venous puncture by a
trained phlebotomist adhering to approved bio-safety pro-
cedures. Two tubes were collected from each participant:
a 10 ml EDTA-anticoagulated blood sample (for in-coun-
try HIV diagnostic testing and sample storage for testing
at the HPTN Network Laboratory) and a 5 ml sample for
CD4 cell count testing; note that CD4 cell count test
results were not analyzed in this substudy. Each blood
sample was assigned a Blood ID number. Tubes were
mixed by inverting 5-8 times, following the manufacturer’s
instructions, immediately after sample collection. Samples
were transported to collaborating local testing laboratories
in cooler boxes following local regulations for transporta-
tion, and were delivered to the testing laboratories within
a sufficient time frame to allow processing and freezing
within 24 hours of sample collection. EDTA-anticoagu-
lated samples were stored and transported at 4-25°C prior
to testing.
In-country testing
In-country HIV diagnostic testing was performed at col-
laborating local testing laboratories according to local
Ministry of Health guidelines. For each participant, the
laboratory performed two HIV rapid tests in parallel.
Testing in Thailand, Tanzania and Zimbabwe was
performed using whole blood; testing at the two South
African sites was performed using plasma. The HIV rapid
tests used at each of the study sites are shown in Table 1.
If both HIV rapid tests were non-reactive, the participant
was considered to be HIV-uninfected; stored samples
from these participants were designated HIV NEG. If
both HIV rapid tests were reactive, the participant was
considered to be HIV-infected; stored samples from
these participants were designated HIV POS. If one of
the two HIV rapid tests was reactive and one of the two
HIV rapid tests was non-reactive (if the HIV rapid tests
results were discordant), a third diagnostic test (tie-
breaker, either an EIA or a third HIV rapid test) was
performed to determine the participant’sH I Vs t a t u s ;
regardless of the results of the third test, samples from
these participants were designated HIV DISC. Each study
site adhered to standards of Good Clinical Laboratory
Practice [10], the HPTN Manual of Laboratory Opera-
tions, and local standard operating procedures for proper
collection, processing, labeling, transport of specimens to
the local testing laboratories, storage, and shipping of
specimens to the HPTN Network Laboratory.
Data management
Specimen collection, testing, storage, and shipping were
tracked using the Laboratory Data Management System
(LDMS). Participant data and laboratory results obtained
at the study sites were submitted to the Project Accept
Statistical Center, where those data were merged and
checked for completeness and consistency. Cleaned data
was submitted to the HPTN Statistical and Data Man-
agement Center (SCHARP, Seattle, WA).
Laboratory testing at the HPTN Network Laboratory
Quality control testing was performed in the HIV Speci-
alty Laboratory at the HPTN Network Laboratory at the
Johns Hopkins University School of Medicine and Johns
Hopkins Hospital (Baltimore, MD); this laboratory is
accredited by the College of American Pathologists and
certified under the Continuous Laboratory Improvement
Act 1988 (CLIA-certified). Testing included the follow-
ing assays: the Vitros EIA Human Immunodeficiency
Virus Type 1 and/or 2 (HIV-1/2) Antibody Detection in
Human Serum and Plasma (VITROS ECi/ECiQ Immu-
nodiagnostic System, Ortho Diagnostics, Johnson &
Johnson, Pencoed, United Kingdom), Genetics System
HIV-1 Western Blot (BioRad Laboratories, Redmond
WA), APTIMA
® HIV-1 RNA Qualitative Assay (Gen-
Probe Inc., San Diego, CA). All assays were performed
according to the manufacturers’ instructions.
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Page 2 of 8Table 1 HIV rapid tests and chemiluminescent immunoassays used at study sites*
Thailand Tanzania Zimbabwe South Africa Vulindlela South Africa Soweto
Assay #1 Determine HIV 1/2
a Determine HIV 1/2
a Determine HIV 1/2
a Determine HIV 1/2
a Determine HIV 1/2
a
Assay #2 Bioline HIV1/2
a,b SD Bioline HIV 1/2 v3
a Uni-Gold HIV
a SD Bioline HIV 1/2 v3
a SD Bioline HIV 1/2 v3
a or Uni-Gold HIV
a
Assay #3 (tie-breaker) Clearview* HIV 1/2 STAT-PAK
c Uni-Gold HIV
a OraQuick HIV-1/2 Rapid Antibody Test
c ARCHITECT HIV Ag/Ab Combo CMIA
c ARCHITECT HIV Ag/Ab Combo CMIA
c
* The following assays were used in the study: Determine HIV 1/2 (Inverness Medical Innovations, Petchabun, Japan), SD Bioline HIV 1/2 version 3 (Youngin-Si, South Korea), Bioline HIV 1/2 (Petchaboon, Thailand),
Uni-Gold HIV (Trinity Biotech plc, Bray, Ireland), Clearview HIV 1/2 STAT-PAK (Inverness Medical Innovations, Waltham, MA), OraQuick HIV 1/2 Rapid Antibody Test (OraSure Technologies, Inc., Bethlehem, PA),
ARCHITECT HIV Ag/Ab Combo (Abbott Diagnostics, Wiesbaden, Germany). CMIA: chemiluminescent microparticle immunoassay.
a Recommended by the USAID [pdf.usaid.gov/pdf_docs/PNADO095.pdf] accessed 11/23/10 - HIV Test Kits Listed in the USAID Source and Origin Waiver: Procurement Information Document, Fifth Edition, Edited by
Abiola Johnson, January 2009].
b Cleared by the Thailand Food and Drug Administration.
c Cleared by the United States Food and Drug Administration.
P
i
w
o
w
a
r
-
M
a
n
n
i
n
g
e
t
a
l
.
B
M
C
I
n
f
e
c
t
i
o
u
s
D
i
s
e
a
s
e
s
2
0
1
1
,
1
1
:
2
5
1
h
t
t
p
:
/
/
w
w
w
.
b
i
o
m
e
d
c
e
n
t
r
a
l
.
c
o
m
/
1
4
7
1
-
2
3
3
4
/
1
1
/
2
5
1
P
a
g
e
3
o
f
8Laboratory testing at Abbott Diagnostics
Samples designated HIV NEG based on in-country testing
were tested using the ARCHITECT HIV Ag/Ab Combo
assay (HIV Combo; List: 2P36; Abbott Diagnostics, Wies-
baden, Germany). HIV Combo testing was performed at
Abbott Diagnostics (Abbott Park, IL). The HIV Combo
assay was performed according to the manufacturers’
instructions, with the following exception: Based on the
package insert, specimens that are initially reactive in the
HIV Combo assay should be retested in duplicate when
the assay is used for HIV diagnosis in a clinical setting. In
this study, the assay was used only to confirm prior test
results for research purposes; the assay was performed
only once to minimize the volume of samples used for this
testing, and any sample that was reactive on this initial
screening test was further evaluated using other assays.
Informed consent
This research was performed in compliance with the Hel-
sinki Declaration. The Project Accept Pilot study was
approved by ethical review committees for each of the
Project Accept study sites and collaborating institutions.
Results
In-country sample collection and testing
In Project Accept, the study team visited households in
the study communities and enrolled eligible participants
who consented for the study (Table 2). Overall, 2,452
(76.3%) of 3,212 members of the selected households
were eligible for the study; 2,247 (91.6%) of the eligible
individuals consented to participate, and had a sample
collected by a trained phlebotomist. Overall, 1,906 parti-
cipants were characterized as HIV-negative (HIV NEG),
24 were characterized as HIV-discordant (HIV DISC),
and 317 were characterized as HIV-positive (see Meth-
ods, Table 2). A third tie-breaker test was used to define
further the infection status of the 24 participants with
discordant HIV rapid tests, but the original designation
of the participants as HIV DISC was not changed in the
study data set.
Evaluation of the accuracy of in-country testing
Samples from participants in the Project Accept pilot
study were analyzed at the HPTN Network Laboratory to
confirm and/or clarify the HIV infection status of each
participant. Test results for each participant group (HIV
NEG, HIV DISC, and HIV POS) are presented below and
in Table 2.
Evaluation of HIV NEG samples
Overall, 1,906 samples had two non-reactive HIV rapid
test results (HIV NEG, Table 2). Those samples were
initially screened using a combined HIV antigen/antibody
test, the ARCHITECT HIV Ag/Ab Combo assay (HIV
Combo, see Methods). This testing confirmed that 1,893
(99.3%) of the 1,906 samples were HIV-negative; the
remaining 14 samples (0.73%) had a reactive HIV Combo
test result. Further testing confirmed that six of the 14
samples were HIV-negative (five samples were non-reac-
t i v ew i t ht h eV i t r o sE I Aa s s a ya n dt h eA P T I M AH I V
RNA test; one sample was reactive with the Vitros EIA,
but had a negative Western blot and was non-reactive
with the APTIMA HIV RNA assay; the median HIV
Combo result for these six samples was signal/cut-off
(s/co) = 3.3, range = 1.3-15.6).
Seven of the remaining eight samples with reactive HIV
Combo test results were confirmed to be HIV-positive;
six were Western blot positive (all from Soweto, HIV
Combo results: median s/co = 438.5, range 395.5-512.2)
and one was Western blot indeterminate (from Tanzania,
HIV Combo result: s/co = 2.71); one sample could not be
evaluated further because there was insufficient plasma
remaining for additional testing (HIV Combo result:
s/co = 3.72; s/co > 1 is considered to be reactive).
Evaluation of HIV DISC samples
Twenty-four samples in the pilot study had discordant
HIV rapid test results (HIV DISC, Table 2); the in-country
tie-breaker test was reactive for three (12.5%) of those
samples. Twenty-two (91.7%) of the 24 samples were non-
reactive with the Vitros EIA and were also non-reactive
with the Aptima HIV RNA test; one sample was reactive
with the Vitros EIA and non-reactive with the Aptima
HIV RNA test. Those 23 samples (95.8% of the 24 HIV
DISC samples) were considered to be HIV-negative; this
includes two samples that had a reactive in-country tie-
breaker test and were identified as HIV-infected based on
in-country testing (one from Tanzania and one from
Vulindlela, South Africa). One sample was reactive with
the Vitros EIA and was Western blot positive; this sample
had a reactive in-country tie-breaker test and was correctly
identified as HIV-positive based on in-country testing.
Evaluation of HIV POS samples
Overall, 317 samples in the pilot study had two reactive
HIV rapid test results (HIV POS, Table 2). Three-hundred-
fifteen (99.4%) of those samples were reactive with the
Vitros EIA and were considered to be HIV-positive,
confirming the in-country test results. The remaining two
samples were non-reactive with the Vitros EIA and were
non-reactive with the Aptima HIV RNA test; those samples
were considered to be HIV-negative (i.e., false positive in-
country test results).
HIV prevalence
HIV prevalence was calculated as: # HIV POS/total #
participants tested × 100% (Table 2). The overall HIV
prevalence based on in-country testing was 14.1%. HIV
prevalence was adjusted to 14.4% based on testing per-
formed at the HPTN Network Laboratory. HIV preva-
lence was 0.6% in Thailand, 5.0% in Tanzania, 14.7% in
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Page 4 of 8Zimbabwe, 19.4% in Soweto, South Africa, and 24.4% in
Vulindlela, South Africa. The overall HIV prevalence at
the three study sites with prevalent subtype C HIV infec-
tion (Zimbabwe and the two sites in South Africa) was
19.8%.
Discussion
Population surveillance of HIV infection is critical for
monitoring the HIV/AIDS epidemic, identifying individuals
in need of HIV care, identifying both HIV-infected and
HIV-uninfected individuals for HIV counseling to reduce
the risk of HIV transmission, and evaluating interventions
for HIV prevention. The widespread availability of HIV
rapid tests has facilitated HIV surveillance. HIV rapid
testing with two or more assays has also replaced use of
Western blots for HIV diagnosis in many countries. In Pro-
ject Accept, HIV surveillance involved collection of blood
samples in communities. At four of the five study sites,
Table 2 Collection and laboratory analysis of samples included in the Project Accept pilot study*
Thailand Tanzania Zimbabwe Soweto South
Africa
Vulindlela South
Africa
Subtype C
(3 sites)
All five
sites
Prevalent HIV subtype(s)
a CRF01_AE Multiple C C C
In-country sample collection and testing
# household members
b 512 683 663 780 574 2,017 3,212
# eligible participants
c 348 417 553 625 509 1,687 2,452
# participants with two HIV rapid test
results
d
341 379 504 530 493 1,527 2,247
# HIV NEG samples 336 348 426 430 366 1,222 1,906
# HIV DISC samples 3 13 3 3 2 8 24
# HIV POS samples 2 18 75 97 125 297 317
HIV prevalence
e 0.6% 4.7% 14.9% 18.3% 25.4% 19.4% 14.1%
Analysis of HIV NEG samples
# HIV Combo reactive
f 3 1 10 11 14
# confirmed HIV-negative 2 1 4 5 7
# HIV-positive, WB positive 6 6 6
# HIV-positive, WB indeterminate 1 1
Analysis of HIV DISC samples
# HIV-negative
g 31 3 3 3 1 7 2 3
# HIV-positive, WB positive
h 11 1
Analysis of HIV POS samples
# HIV-negative
i 11 2 2
Corrected sample numbers
j
Corrected # HIV NEG samples 339 360 430 427 368 1,225 1,924
Corrected # HIV POS samples 2 19 74 103 125 302 323
Corrected HIV prevalence 0.6% 5.0% 14.7% 19.4% 24.4% 19.8% 14.4%
*WB: Western blot; OD-n: normalized optical density units; POS: positive; DISC: discordant; NEG: negative.
aThe prevalent HIV subtypes at each site are indicated. Most HIV strains in Thailand are CRF01_AE. Multiple HIV subtypes are prevalent in Tanzania, including HIV
subtypes A, C, and D. Most HIV infections in South Africa and Zimbabwe are subtype C. The column labeled “Subtype C” shows combined results from Vulindlela
and Soweto, South Africa, and Zimbabwe.
bAll household members (see Methods)
cNumber (#) eligible participants excludes participants who had no contact, declined participation, were ineligible for the study, or had missing status.
dSamples were characterized based on the results of the two HIV rapid tests (see Methods): HIV POS: two reactive HIV rapid tests. HIV DISC: one reactive and one
non-reactive HIV rapid test. HIV NEG: two non-reactive HIV rapid tests.
eHIV prevalence based on in-country testing: # HIV POS samples/total # samples × 100.
fFourteen samples were initially reactive with the ARCHITECT HIV Ag/Ab Combo assay (HIV Combo, signal/cutoff >1). Note that according to the package insert,
specimens that are initially reactive with HIV Combo must be retested in duplicate and only repeatedly reactive specimens are considered reactive. In this study,
samples were analyzed only once because sample volumes were limiting.
gTwenty-two samples were non-reactive with the Vitros EIA and non-reactive with the Aptima HIV RNA test; one sample was reactive with the Vitros EIA and
non-reactive with the Aptima HIV RNA test.
hOne sample was reactive with the Vitros EIA and was Western blot positive.
iTwo samples were non-reactive with the Vitros EIA and non-reactive with the Aptima HIV RNA test.
jCorrected sample numbers: The numbers of HIV POS and HIV NEG samples were adjusted by taking into account reclassification of samples based on quality
control testing performed at the HPTN Network Laboratory.
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one study site (Thailand), the vast majority of blood collec-
tion was performed at a community center, with only a
small number of samples collected in home-based settings.
Samples were transported to local laboratories for testing
by trained and certified Medical Technologists. Those
laboratories demonstrated successful performance in Exter-
nal Quality Control programs, and were also monitored
and audited by the HPTN Network Laboratory, the HPTN
Statistical and Data Management Center, the National
Institutes of Health (NIH) Division of Allergy and Infec-
tious Diseases (NIAID), and an external monitoring group
as part of this HPTN clinical trial. For these reasons, the
accuracy of laboratory testing, data and sample manage-
ment may be higher in this study than in other clinical and
field-based HIV surveillance settings (e.g., where HIV rapid
testing is performed in a non-laboratory or home-based
setting by non-laboratory health workers). However, adding
external improvement measures can improve the perfor-
mance of such HIV rapid testing [11] and multiple rapid
test algorithms have been shown to be very accurate when
used in diverse African settings [12-14]. In the Project
Accept pilot study, the requirement for real-time CD4 cell
count testing and sample storage for quality control and
other testing at the HPTN Network Laboratory necessi-
tated use of phlebotomy (rather than finger-stick) for all
Project Accept participants; the post-intervention assess-
ment phase of Project Accept has similar requirements for
sample collection and testing. Data from the pilot study of
Project Accept (this report) and the on-going post-inter-
vention assessment (data not shown) demonstrate high
rates of acceptance and success of phlebotomy performed
in communities, mostly in home-based settings. Among
2,452 eligible participants, 2,299 (93.7%) consented to par-
ticipate in the Project Accept pilot study; 2,247 (97.7%) of
those participants had two HIV rapid tests obtained in-
country and had samples stored and shipped to the HPTN
Network Laboratory for testing. This demonstrates the
feasibility of using this approach for community-based
research studies. In the Project Accept pilot study, partici-
pants were provided with pre-test counseling and informa-
tion about how to access their in-country test results.
Participants who accessed their test results were provided
with post-test counseling, and those with positive test
results were referred to treatment centers. However, most
participants did not seek their results. In other studies,
such as those that include a “test and treat” objective, HIV
rapid testing in the field using a finger-stick sample (with
or without subsequent phlebotomy for those who are
likely to be HIV-infected) would allow for real-time com-
munication of HIV test results and referral for HIV care
and treatment.
We detected relatively low rates of false positive and
false negative on-site test results; HIV status based on
analysis of samples at the HPTN Network Laboratory
was different from the HIV status based on in-country
testing for 11 (0.5%) of 2,247 study participants. Seven
(0.37%) of 1,906 samples identified in-country as HIV
NEG were found to be HIV-positive. Those samples were
identified by testing the HIV NEG samples with the HIV
Combo assay, which is similar in cost to other automated
serologic assays used for HIV diagnosis. The HIV Combo
assay can detect acute (pre-seroconversion) HIV infec-
tion, as well as established (antibody-positive) HIV infec-
tion; the sensitivity for detection of acute infection with
HIV Combo is similar to typically pooled HIV RNA test
methods [15-18]. We did not detect any acute HIV infec-
tions among the 1,906 HIV NEG samples screened with
the HIV Combo assay. Two (0.63%) of 317 samples iden-
tified in-country as HIV POS were found to be HIV-
negative. In addition, two of the three participants with
discordant HIV rapid tests who had a reactive in-country
tie-breaker test and were identified in-country as HIV-
infected were found to be HIV-negative based on testing
at the HPTN Network Laboratory. It is not possible to
determine whether these errors (false negative and false
positive HIV results) were due to problems with partici-
pant identification/sample labeling, testing errors, or
clerical errors at the study sites.
In the Project Accept pilot study, the HIV prevalence
across the five study sites based on in-country HIV rapid
testing was 14.1%. This was adjusted to 14.4% when test
results from the HPTN Network Laboratory were taken
into account. The HIV prevalence varied widely across
the study sites, from 0.6% in Thailand to 24.4% in Vulin-
dlela, South Africa. The highest HIV prevalence rates
were found at the three sites where subtype C is preva-
lent (Zimbabwe and the two sites in South Africa, overall
19.8%).
Conclusions
This study provides information on the accuracy of HIV
surveillance testing performed in the context of a clini-
cal trial, where testing was performed in local labora-
tories in Thailand, Tanzania, Zimbabwe and South
Africa. In-country testing based on two HIV rapid tests
correctly identified the HIV infection status for 99.5% of
study participants; most participants with discordant
HIV rapid tests were not infected. HIV prevalence var-
ied considerably across the five Project Accept study
sites (range: 0.6% to 25.4%). Further studies are needed
to assess the accuracy of HIV testing in surveillance and
clinical programs where testing is performed in non-
laboratory (e.g., home-based) settings. Further research
is also needed to identify and validate robust, accurate
methods for cross-sectional HIV incidence determina-
tion that could easily be incorporated into HIV surveil-
lance programs.
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